Dianthus Therapeutics earnings up next as trial data looms

Dianthus Therapeutics Inc. is scheduled to release its third-quarter earnings on Thursday. Analysts have a strong buy consensus for the stock, with a mean price target of $139.06, indicating a 68% upside from its current price of $82.70. The company anticipates a loss of $0.94 per share and revenue of $443,850 for the quarter ending in September, which would be a decline from the prior quarter's loss of $0.09 per share and revenue of $760,000—both figures surpassing expectations.

All 18 analysts covering the company rate it a buy, with no holds or sells. Roth/MKM began covering the stock in late October, maintaining a buy rating and $113 price target, citing claseprubart, Dianthus' lead drug candidate, as potentially superior to any existing option for multiple neuromuscular diseases. Analysts have observed a 22.34% rise in revenue estimates over the past 60 days, while EPS estimates have remained relatively stable, suggesting increasing confidence in the company's financial outlook despite its cash burn to support clinical programs.

Investors will be focused on fourth-quarter 2026 trial data from the Phase 2 MMN trial, year-end guidance for Phase 3 CIDP enrollment, and readout timing. The company's $1.19 billion cash balance, which analysts view as sufficient until 2030, will also be scrutinized. Any changes to the cash runway guidance could impact the stock's price, especially considering Dianthus' ambitious plans to advance claseprubart in generalized myasthenia gravis, CIDP, and MMN through pivotal trials.